Opinion|Videos|October 22, 2024
68Gallium PSMA-11 PET-CT Imaging vs Conventional Imaging Techniques
Author(s)Oliver Sartor, MD
Key Takeaways
- Gallium PSMA-11 gozetotide is effective in detecting prostate cancer metastases and assessing biochemical recurrence with high sensitivity and specificity.
- The tracer is particularly useful for identifying small lesions and lymph node involvement in prostate cancer patients.
The panelist discusses how 68gallium prostate-specific membrane antigen-11 (PSMA-11) gozetotide is most useful in PET-CT imaging for detecting and staging prostate cancer.
Advertisement
In what situations would you use 68gallium prostate-specific membrane antigen-11 gozetotide in PET-CT imaging? In what situations would this tracer be less useful?
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: September 2026
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD
5